ReviewFrontiers in nutrition2026
Revisiting the need for innovative oral hydration technologies.
Review in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral rehydration therapy (ORT) is an important component of fluid management in people with dysregulated fluid intake, renal disorders, and inflammatory gastrointestinal diseases. During intense exercise or periods of compromised intestinal water absorption, regulated intake of an oral rehydration solution (ORS) promotes water uptake and replenishes depleted micronutrients. The primary components of ORS formulation are sodium and glucose, which are co-transported across the apical membrane of ileal and jejunal epithelia to create an osmotic gradient favorable to water uptake. ORS designed for specific conditions are formulated with additional sugars, starches, micronutrients, and proteins to enhance water uptake and counteract solute loss. Despite its efficacy in preventing mortality in children with watery diarrhea, and its demonstratable benefits over intravenous fluid replacement in clinical applications, there is a lack of recent published developments in ORS technology. Recent developments have been driven by the sports nutrition industry, particularly in targeted delivery of carbohydrates. These proprietary developments have potential applications in ORS formulation to improve chronic disease outcomes and enhance acute fluid retention during clinical crises. This review aims to summarize recent literature investigating ORS formulation and application with a focus on chronic disease and exercise rehydration, as well as demonstrate the opportunity for development of new rehydration technologies for both general fluid maintenance and clinical fluid replacement therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.